# A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct06996782/  
OnCo record `nct06996782` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rilvegostomig, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.

## Summary

A Platform Study in Non-Small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT06996782 by AstraZeneca, with 152 participants planned, started 2025-11-24 and due to reach its primary completion in 2029-02-23. Interventions recorded: Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06996782
- Phase: 1/2
- Setting: A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: AstraZeneca
- Enrolled: 152

## Sources

- ClinicalTrials.gov NCT06996782: https://clinicaltrials.gov/study/NCT06996782

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06996782.json